Is AxonDAO's Psylosis, the First of Its Kind?

Psylosis is one of the pioneering DeSci initiatives in the US integrating AI, blockchain, and IRB-approved ethical protocols. This ensures the process and data security meet the highest standards for safety, privacy, and data integrity.

Did you know that from 1955 to 2021, there have only been 19 studies on microdosing psychedelics, with an average of 22 participants per study. There have been no (0) known clinical trials combining microdosing psilocybin with voice AI analysis.

Microdosing Research:
Most studies focus on full (Macro) doses due to regulatory preferences for larger, measurable impacts.

Voice AI Technology:
AI-driven voice analysis forl health is new and experimental in psychedelics research.

Pioneering Efforts:
Psylosis bridges traditional methods with innovative AI and DeSci approaches.

Biometric data provided by your voice for Psylosis, into CureOS is an objective, quantifiable measurement of psilocybin's effects, complementing subjective reports. This multimodal approach improves understanding of its impact on the brain and body, advancing safe and effective therapies.

Psilocybin, the active ingredient in magic mushrooms, has been increasingly studied. By 2021, 13 phase II trials worldwide examined its use (in full doses) for treating depression. These studies reflect rising interest in its therapeutic potential.

However, this field is still emerging. Ongoing trials are needed to better understand psilocybin's safety and efficacy across medical conditions, and proper legal jurisdictions.

To sign up for the Psylosis Project, updates, and its commitment to ethical research practices, visit our site axondao(dot)io